ストックスクリーナーアプリを入手
2.27
0.87%
-0.02
アフターアワーズ：
2.23
-0.04
-1.76%
前日終値:
$2.29
開ける：
$2.34
24時間の取引高:
7,603
Relative Volume:
0.01
時価総額：
$15.93M
収益：
$2.43M
当期純損益:
$-11.03M
株価収益率:
0.0357
EPS:
63.6476
ネットキャッシュフロー:
$-3.75M
1週間 パフォーマンス:
+9.13%
1か月 パフォーマンス:
-34.58%
6か月 パフォーマンス:
-58.04%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.27
$2.34
1週間の範囲:
$2.06
$2.405
52週間の値動き範囲:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Compare HIND vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.27 | 16.07M | 2.43M | -11.03M | -3.75M | 63.65 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Vyome Holdings Inc (HIND) 最新ニュース
Vyome Holdings, Inc.: Fundamental Analysis and Financial Ratings | H1O | US92943X1046 - marketscreener.com
Vyome Holdings Reports Positive Phase 2 Clinical Results for VT-1953 Topical Gel in Malignant Fungating Wounds and Acne Treatment – 2026 Company Overview and Pipeline Update - Minichart
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
HIND Should I Buy - Intellectia AI
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Head to Head Review: Vyome (HIND) and Its Rivals - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
HIND Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace
Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Penny Stocks To Follow Now – January 27th - Defense World
Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer
Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com
Hindustan Diverges: Financial Snapshot Paints Varied Picture - StocksToTrade
Vyome Holdings Inc (HIND-Q) Stock Price and News - The Globe and Mail
Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com
Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Vyome Holdings Inc (HIND) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):